Safety and Preliminary Efficacy of MT-601 in Patients With Relapsed/Refractory Lymphoma
Clinical trial NCT05798897 · RECRUITING
Trial details
- NCT number
- NCT05798897
- Sponsor
- Marker Therapeutics, Inc.
- Status
- RECRUITING
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2023-01-02
- Primary completion
- 2028-02-28
- Enrollment
- 79
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.